{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T22:27:20Z","timestamp":1791584840433,"version":"4.3.4"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,1,9]],"date-time":"2024-01-09T00:00:00Z","timestamp":1704758400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,1,9]],"date-time":"2024-01-09T00:00:00Z","timestamp":1704758400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Ovarian Res"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Objective<\/jats:title>\n                <jats:p>To investigate the effect of L-carnitine supplementation during the controlled ovarian stimulation (COS) cycle with antagonist protocol in patients with polycystic ovary syndrome (PCOS) diagnosis undergoing IVF\/ICSI treatment.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods and materials<\/jats:title>\n                <jats:p>This was a double-blind clinical trial study including 110 patients with PCOS attended to Royan Institute between March 2020 and February 2023. At the beginning of the COS cycle, the eligible patients were allocated into two groups randomly according to the coding list of the drugs prepared by the statistical consultant. In the experimental group, patients received 3 tablets daily (L-carnitine 1000\u2009mg) from the second day of menstruation of the previous cycle until the puncture day in the cases of freeze-all embryos (6\u2009weeks) or until the day of the pregnancy test (8\u2009weeks) in fresh embryo transfer cycle. In the control group, patients received 3 placebo tablets for the same period of time. Weight assessment and fasting blood sugar and insulin tests, as well as serum lipid profile were also measured at the baseline and ovum pick-up day. The results of the COS cycle as well as the implantation and pregnancy rates were compared between groups.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Finally, 45 cases in L-carnitine group versus 47 cases in the placebo group were completed study per protocol. Data analysis showed that the two groups were homogeneous in terms of demographic characteristics and baseline laboratory tests and severity of PCOS. There is no statistically significant difference in terms of the oocyte recovery ratio and oocyte maturity rate, and the number and quality of embryos, as well as the rates of the fertilization, chemical and clinical pregnancy between groups. However, the means of weight (<jats:italic>P<\/jats:italic>\u2009&lt;\u20090.001) and serum levels of fasting blood sugar (<jats:italic>P<\/jats:italic>\u2009=\u20090.021), fasting insulin (<jats:italic>P<\/jats:italic>\u2009=\u20090.004), triglyceride (<jats:italic>P<\/jats:italic>\u2009&lt;\u20090.001) and cholesterol (<jats:italic>P<\/jats:italic>\u2009&lt;\u20090.001), LDL (<jats:italic>P<\/jats:italic>\u2009&lt;\u20090.001) have significantly decreased in women after consuming L-carnitine supplementation.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>The oral intake of L-carnitine during COS in PCOS women for 6\u2009weeks had no effect on COS and pregnancy outcomes. However, taking this supplement for 6\u2009weeks has been associated with weight loss and improved lipid profile and serum glucose.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Trial registration<\/jats:title>\n                <jats:p>The study was registered in the Clinicaltrials.gov  site on December 17, 2020 (NCT04672720).<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s13048-023-01319-7","type":"journal-article","created":{"date-parts":[[2024,1,9]],"date-time":"2024-01-09T03:01:49Z","timestamp":1704769309000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Adding L-carnitine to antagonist ovarian stimulation doesn\u2019t improve the outcomes of IVF\/ ICSI cycle in patients with polycystic ovarian syndrome: a double-blind randomized clinical trial"],"prefix":"10.1186","volume":"17","author":[{"given":"Maryam","family":"Hafezi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arezoo","family":"Arabipoor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Firouzeh","family":"Ghaffari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samira","family":"Vesali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maryam","family":"Zareei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zahra Hajinaghibali","family":"Hessari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,1,9]]},"reference":[{"key":"1319_CR1","volume-title":"Polycystic ovary syndrome: causes","author":"K Webb","year":"2021","unstructured":"Webb K. Polycystic ovary syndrome: causes. Diagnosis and Management: Nova Science Publishers; 2021."},{"issue":"5\u20136","key":"1319_CR2","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1016\/j.mam.2004.06.006","volume":"25","author":"A Steiber","year":"2004","unstructured":"Steiber A, Kerner J, Hoppel CL. Carnitine: a nutritional, biosynthetic, and functional perspective. Mol Asp Med. 2004;25(5\u20136):455\u201373. Epub 2004\/09\/15","journal-title":"Mol Asp Med"},{"issue":"1","key":"1319_CR3","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.yexcr.2005.01.019","volume":"306","author":"RT Pillich","year":"2005","unstructured":"Pillich RT, Scarsella G, Risuleo G. Reduction of apoptosis through the mitochondrial pathway by the administration of acetyl-L-carnitine to mouse fibroblasts in culture. Exp Cell Res. 2005;306(1):1\u20138. Epub 2005\/05\/10","journal-title":"Exp Cell Res"},{"issue":"2","key":"1319_CR4","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1023\/A:1007638025856","volume":"16","author":"A Vanella","year":"2000","unstructured":"Vanella A, Russo A, Acquaviva R, et al. L -propionyl-carnitine as superoxide scavenger, antioxidant, and DNA cleavage protector. Cell Biol Toxicol. 2000;16(2):99\u2013104. Epub 2000\/08\/05","journal-title":"Cell Biol Toxicol"},{"issue":"4","key":"1319_CR5","doi-asserted-by":"publisher","first-page":"824","DOI":"10.1007\/s00125-007-0605-4","volume":"50","author":"RA Power","year":"2007","unstructured":"Power RA, Hulver MW, Zhang JY, et al. Carnitine revisited: potential use as adjunctive treatment in diabetes. Diabetologia. 2007;50(4):824\u201332. Epub 2007\/02\/21","journal-title":"Diabetologia"},{"issue":"7","key":"1319_CR6","doi-asserted-by":"publisher","first-page":"1602","DOI":"10.1093\/humrep\/den109","volume":"23","author":"SM Fenkci","year":"2008","unstructured":"Fenkci SM, Fenkci V, Oztekin O, Rota S, Karagenc N. Serum total L-carnitine levels in non-obese women with polycystic ovary syndrome. Hum Reprod. 2008;23(7):1602\u20136. Epub 2008\/04\/02","journal-title":"Hum Reprod"},{"issue":"1","key":"1319_CR7","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s00394-011-0284-2","volume":"51","author":"R Ringseis","year":"2012","unstructured":"Ringseis R, Keller J, Eder K. Role of carnitine in the regulation of glucose homeostasis and insulin sensitivity: evidence from in vivo and in vitro studies with carnitine supplementation and carnitine deficiency. Eur J Nutr. 2012;51(1):1\u201318. Epub 2011\/12\/03","journal-title":"Eur J Nutr"},{"issue":"4","key":"1319_CR8","doi-asserted-by":"publisher","first-page":"674","DOI":"10.1016\/j.freeradbiomed.2010.05.025","volume":"49","author":"K Miyamoto","year":"2010","unstructured":"Miyamoto K, Sato EF, Kasahara E, et al. Effect of oxidative stress during repeated ovulation on the structure and functions of the ovary, oocytes, and their mitochondria. Free Radic Biol Med. 2010;49(4):674\u201381. Epub 2010\/07\/14","journal-title":"Free Radic Biol Med"},{"key":"1319_CR9","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1016\/j.ejogrb.2014.06.008","volume":"180","author":"AM Ismail","year":"2014","unstructured":"Ismail AM, Hamed AH, Saso S, Thabet HH. Adding L-carnitine to clomiphene resistant PCOS women improves the quality of ovulation and the pregnancy rate. A randomized clinical trial. Eur J Obstet Gynecol Reprod Biol. 2014;180:148\u201352. Epub 2014\/07\/13","journal-title":"Eur J Obstet Gynecol Reprod Biol"},{"issue":"11","key":"1319_CR10","doi-asserted-by":"publisher","first-page":"941","DOI":"10.2165\/00003088-200342110-00002","volume":"42","author":"AM Evans","year":"2003","unstructured":"Evans AM, Fornasini G. Pharmacokinetics of L-carnitine. Clin Pharmacokinet. 2003;42(11):941\u201367.","journal-title":"Clin Pharmacokinet"},{"issue":"1","key":"1319_CR11","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12958-018-0323-4","volume":"16","author":"A Agarwal","year":"2018","unstructured":"Agarwal A, Sengupta P, Durairajanayagam D. Role of L-carnitine in female infertility. Reprod Biol Endocrinol. 2018;16(1):1\u201318.","journal-title":"Reprod Biol Endocrinol"},{"issue":"1","key":"1319_CR12","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/j.fertnstert.2003.10.004","volume":"81","author":"TR Eshre","year":"2004","unstructured":"Eshre TR, Group A-S P C W. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. Fertil Steril. 2004;81(1):19\u201325.","journal-title":"Fertil Steril"},{"issue":"1","key":"1319_CR13","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1016\/j.fertnstert.2016.05.003","volume":"106","author":"D Lizneva","year":"2016","unstructured":"Lizneva D, Suturina L, Walker W, Brakta S, Gavrilova-Jordan L, Azziz R. Criteria, prevalence, and phenotypes of polycystic ovary syndrome. Fertil Steril. 2016;106(1):6\u201315.","journal-title":"Fertil Steril"},{"issue":"6","key":"1319_CR14","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1111\/cen.13003","volume":"84","author":"M Samimi","year":"2016","unstructured":"Samimi M, Jamilian M, Ebrahimi FA, Rahimi M, Tajbakhsh B, Asemi Z. Oral carnitine supplementation reduces body weight and insulin resistance in women with polycystic ovary syndrome: a randomized, double-blind, placebo-controlled trial. Clin Endocrinol. 2016;84(6):851\u20137. Epub 2015\/12\/17","journal-title":"Clin Endocrinol"},{"issue":"4","key":"1319_CR15","first-page":"392","volume":"23","author":"S Salehpour","year":"2019","unstructured":"Salehpour S, Nazari L, Hoseini S, Moghaddam PB, Gachkar L. Effects of L-carnitine on polycystic ovary syndrome. JBRA Assist Reprod. 2019;23(4):392\u20135.","journal-title":"JBRA Assist Reprod"},{"key":"1319_CR16","doi-asserted-by":"crossref","unstructured":"Moawad AR, Tan SL, Xu B, Chen HY, Taketo T. L-carnitine Supplementation during vitrification of mouse oocytes at the germinal vesicle stage improves preimplantation development following maturation and fertilization in vitro. Biol Reprod. 2013;88(4)","DOI":"10.1095\/biolreprod.112.107433"},{"key":"1319_CR17","first-page":"1","volume":"1","author":"A Sheida","year":"2021","unstructured":"Sheida A, Davar R, Tabibnejad N, Eftekhar M. The effect of adding L-carnitine to the GnRH-antagonist protocol on assisted reproductive technology outcome in women with polycystic ovarian syndrome: a randomized clinical trial. Gynecol Endocrinol. 2021;1:1\u20135.","journal-title":"Gynecol Endocrinol"},{"issue":"5","key":"1319_CR18","doi-asserted-by":"publisher","first-page":"4138","DOI":"10.21608\/ejhm.2019.43079","volume":"76","author":"AT Abd-Elfattah","year":"2019","unstructured":"Abd-Elfattah AT, E-a EFA, Hashish MA-E, Megahed HI. Effect of adding L-carnitine to clomiphene resistant PCOs women on the ovulation and the pregnancy rate. The Egyptian Journal of Hospital Medicine. 2019;76(5):4138\u201343.","journal-title":"The Egyptian Journal of Hospital Medicine"},{"issue":"1","key":"1319_CR19","doi-asserted-by":"publisher","first-page":"1","DOI":"10.21608\/ebwhj.2019.17527.1032","volume":"10","author":"M Kortam","year":"2020","unstructured":"Kortam M, Abdelrahman R, Fateen H. L-Carnitine And clomiphene citrate for induction of ovulation in women with polycystic ovary syndrome : randomized controlled trial. Evidence Based Women's Health Journal. 2020;10(1):1\u20137.","journal-title":"Evidence Based Women's Health Journal"},{"issue":"8","key":"1319_CR20","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1080\/09513590.2019.1576622","volume":"35","author":"I El Sharkwy","year":"2019","unstructured":"El Sharkwy I, Sharaf E-DM. l-Carnitine Plus metformin in clomiphene-resistant obese PCOS women, reproductive and metabolic effects: a randomized clinical trial. Gynecol Endocrinol. 2019;35(8):701\u20135.","journal-title":"Gynecol Endocrinol"},{"key":"1319_CR21","unstructured":"Kitano Y, Hashimoto S, Matsumoto H, et al. Oral administration of l-carnitine improves the clinical outcome of fertility in patients with IVF treatment. Gynecol Endocrinol. 2018;1-5"},{"key":"1319_CR22","volume-title":"National Institutes of Health third report of the National Cholesterol Education Program Expert Panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel III)","author":"Health N I o","year":"2001","unstructured":"Health N I o. National Institutes of Health third report of the National Cholesterol Education Program Expert Panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel III). Executive Summary. Lung, and Blood Institute; 2001."}],"container-title":["Journal of Ovarian Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13048-023-01319-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13048-023-01319-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13048-023-01319-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,9]],"date-time":"2024-01-09T14:04:05Z","timestamp":1704809045000},"score":1,"resource":{"primary":{"URL":"https:\/\/ovarianresearch.biomedcentral.com\/articles\/10.1186\/s13048-023-01319-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,9]]},"references-count":22,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["1319"],"URL":"https:\/\/doi.org\/10.1186\/s13048-023-01319-7","relation":{},"ISSN":["1757-2215"],"issn-type":[{"value":"1757-2215","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,1,9]]},"assertion":[{"value":"12 September 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 December 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 January 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of Royan Institute and the 1964 Helsinki declaration and its later amendments or comparable ethical standards (Ethics approval number: IR.ACECR.ROYAN.REC.1397.156). The eligible patients signed written informed consent prior to participation in the study<i>.<\/i>","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"9"}}